BioSpace News Archive

InMed Pharmaceuticals Inc. reported financial results for the three months ended September 30, 2019, which is the Company’s first quarter of fiscal year 2020.

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it will host a KOL Symposium for investors on Friday, November 15, 2019 from 8:15 a.m. to 10:00 a.m. ET in New York, NY.

Supplemental New Drug Application -- submitted through FDA Real-Time Oncology Review program -- is based on positive Phase 3 data in patients aged 70 or younger

Bio-Path Holdings, Inc., (NASDAQ: BPTH), today announced that it will host a live conference call and audio webcast on Friday, November 15, 2019 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2019 and to provide a business overview

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, reports positive interim data from its open label TACTI-002 Phase II clinical trial, building on the first top line data reported on 26 September 2019.

Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today provided financial results and corporate updates for its second fiscal quarter ended September 30, 2019.

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the third quarter ended September 30, 2019 and provided pipeline updates.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the launch of its OR3O Dual Mobility System for use in primary and revision hip arthroplasty

Company provides updates on recent financing and advancements in its product candidates Mino-Lok®, Mino-Wrap™, and Halo-Lido

BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, announced its financial results for the third quarter ended September 30, 2019 and provided a corporate update.